期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺肿瘤组织中EGFR与EGFRv Ⅲ的表达及临床意义 被引量：5

Expressions and clinical significance of EGFR and EGFRv Ⅲ in mammary tumor
下载PDF
导出
摘要 目的:探讨EGFR和EGFRvⅢ在人乳腺癌及乳腺良性增生性疾病中的表达及临床意义。方法:应用Supervi-sionTM免疫组化方法检测30例乳腺良性增生性病变、病变旁及55例乳腺癌、癌旁和转移淋巴结组织的EGFR、EGFRvⅢ的表达。结果:EGFR在乳腺癌表达72.7%,癌旁29.1%,转移淋巴结58.3%(χ2=5.326,P=0.021);EGFRvⅢ在乳腺癌表达52.7%,癌旁1.8%,转移淋巴结45.8%(χ2=4.718,P=0.030)。EGFR表达与病理分级(χ2=11.840,P=0.002)、转移淋巴结数目(χ2=13.715,P=0.000)、ER阴性(χ2=10.785,P=0.007)、PR阴性(χ2=4.727,P=0.031)相关;EGFRvⅢ与病理分级(χ2=5.280,P=0.024)、有无远处转移(χ2=5.612,P=0.019)、淋巴结转移数目(χ2=4.464,P=0.038)、ER阴性(χ2=3.960,P=0.049)、PR阴性(χ2=17.517,P=0.000)和c-erbB-2阳性(χ2=7.424,P=0.005)相关。结论:EGFR、EGFRvⅢ过度表达可能与乳腺癌发生发展密切相关,EGFRvⅢ有望作为预测乳腺癌临床预后候选基因之一。 OBJECTIVE： To explore the expressions and clinical significanee of EGFR and EGFRv Ⅲ in human breast cancer tissues and benign mammary hyperplasia. METtlODES： SupervisionTM immunohistochemical staining （IHC） was used to detect the expressions of EGFR and EGFRv HI in 30 specimens of human benign mammary hyperplasia tissues, 55 specimens of human breast cancer tissues, all their adjacent non-cancerous mammary tissues and metastasis lymph nodes. RESULTS： The positive rate of EGFR in breast cancer tissues was significantly higher than that in adjaeent non-cancerous mammary tissues and metastasis lymph node tissues （72.7%, 29.1% vs 58.3%, X^2 = 5. 326,P=0. 021）. The positive rate of EGFRv Ⅲ in breast cancer tissues was significantly higher than that in adjacent non-cancerous mammary tissues and metastasis lymph node tissues （52.7%, 1.8% vs 45.8%, X^2=4.718,P=0.030）. The positive rate of EGFR was significantly correlated with the pathologic grade （X^2 = 11.840, P = 0. 002）, the number of local metastasis LN （X^2 =13. 715,P=0. 000） , ER-（X^2=10. 785,P=0. 007） and PR-（X^2 =4. 727,P=0. 031）. The positive rate of EGFRv Ⅲ was significantly correlated with the pathologic grade （X^2 =5. 280,P=0. 024）, distant metastasis （X^2 =5. 612, P=0.019）, the number of local metastasis LN （X^2 =4.464, P= 0. 038）, ER- （X^2 =3. 960,P=0. 049）, PR-（X^2 =17. 517,P=0. 000） and c-erbB-2 ＋ （X^2 = 7. 424, P= 0. 005）. CONCLUSION： Over-ex- pressed EGFR and EGFRvⅢ may be really related to initiation and progression of breast cancer. EGFRvⅢ could be considered as the marker for predicting the initiation and prognosis of human breast cancer.
作者 赵荫农 何妮 欧超 曹骥 陈军 刘剑勇 袁卫平
机构地区 广西医科大学附属肿瘤医院肝胆乳腺外科 广西壮族自治区民族医院普外科 广西医科大学附属肿瘤医院病理科
出处 《中华肿瘤防治杂志》 CAS 2007年第3期185-188,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤/病理学 乳腺纤维囊性病 受体 表皮生长因子 免疫组织化学 breast neoplasms/pathology fibrocystic breast disease receptor, epidermal growth factor immunohistochemistry
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1宋振川,王桂兰,齐义新,崔东臣,李勇.MTS1及E-cadherin的表达与乳腺癌转移的关系[J].癌症,2003,22(5):526-528. 被引量：11
  • 2Yaden Y,Sliwkowski M X.Untangling the ErbB signaling network[J],Nat Rev Mol Biol,2001,2(2):127-137.
  • 3Brideges A J.The rationale and strategy used to develop a series of highly potent,irreversible,inhibitors of The epidermal growth factor receptor family of tyrosine kinases[J].Curr Med Chem,1999,6(9):825-843.
  • 4Wikstrand C J,Reist C J,Archer G E,et al,The Class Ⅲ variant of epidermal growth factor receptor(EGFRv Ⅲ):Charaterization and utilization as immunotherapeutie target[J].J Neuroviro,1998,4(2):148-158.
  • 5Klapper L N,kirschbaum M A,Sela M,et al.Biochemical and clinical implications of the ErbB/HER signaling network of growth facter receptors[J].Adv Cancer Res,2000,77(10):25-79.
  • 6Moscatello D K,Holado-Madruga M,Godwin A K,et al.Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors[J].Cancer Res,1995,55(23):5536-5539.
  • 7Wikstrand C J,Reist C J,Archer G E,et al.The Class Ⅲ variant of epidermal growth factor receptor(EGFRv Ⅲ):Charaterization and utilization as immunotherapeutie target[J].J Neuroviro,1998,4(2):148-158.
  • 8Pedersen M W,Meltorn M,Damstrll P L,et al.The type Ⅲ epidermal growth factor receptor mutation,biological,Significant and potential target for anti-cancer therapy[J].Ann Oncol,2001,12(6):745-10.
  • 9欧超,吴飞翔,罗元,曹骥,赵荫农,袁卫平,李瑗,苏建家.表皮生长因子受体Ⅲ型突变体在肝细胞癌中的表达及意义[J].癌症,2005,24(2):166-169. 被引量：19
  • 10Damstrup L,Wandahl R M,Basthoiml,et al.Epidermal growth factor receptor mutation type transfected into a small sell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype[J].Int J Cancer,2002,97(1):7-14.

二级参考文献17

  • 1Shirakata Y, Komurasaki T, Toyoda H, et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes [J]. J Biol Chem, 2000,275 ( 8 ) : 5748-5753.
  • 2Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme [ J ]. Cancer Res, 2003,63 (20) : 6962-6970.
  • 3Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the v Ⅲ mutation of human epidermal growth factor receptor [J]. Tumour Biol, 2002,23(2) :61-69.
  • 4Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy [J]. Curr Cancer Drug Targets, 2002,2(2):91-102.
  • 5Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion [J]. Cancer Res, 2002,62(12) :3335-3339.
  • 6Luo X, Gong X, Tang CK. Suppression of EGFRv Ⅲ-mediatedproliferation and tumorigenesis of breast cancer cells by ribozyme [J]. Int J Cancer, 2003,104(6) :716-721.
  • 7Lavictoire SJ, Parolin DA, Klimowicz AC, et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRv Ⅲ [J]. J Biol Chem, 2003,278(7):5292-5299.
  • 8Okamoto I, Kenyon LC, Emlet DR, et al. Expression of constitutively activated EGFRv Ⅲ in non-small cell lung cancer[J]. Cancer Sci, 2003,94( 1 ) :50-56.
  • 9Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours [J]. Cancer Treat Rev, 2004,30(1):1-17.
  • 10Wikstrand CJ, Reist C J, Archer GE, et al. The class Ⅲ variant of the epidermal growth factor receptor [EGFRv Ⅲ]:characterization and utilization as an immunotherapeutic target[J]. J Neurovirol, 1998,4(2) : 148-158.

共引文献28

同被引文献40

  • 1欧超,吴飞翔,罗元,曹骥,赵荫农,袁卫平,李瑗,苏建家.表皮生长因子受体Ⅲ型突变体在肝细胞癌中的表达及意义[J].癌症,2005,24(2):166-169. 被引量：19
  • 2马树东,罗荣城,丁彦青,刘来煜,蔡俊杰.乳腺癌组织中EGFR、IGF-1R、HER2/neu和p53蛋白的表达及意义[J].肿瘤防治杂志,2005,12(5):335-338. 被引量：12
  • 3杨栋,戎彪学,蔡曦光.基质金属蛋白酶MMP-2与肺癌关系的研究进展[J].国外医学（老年医学分册）,2006,27(2):89-92. 被引量：3
  • 4Pawlowski V, Revillion F, Hebbar M, et al. Prognostic value of the type Ⅰ growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay [ J ] . Clin Cancer Res, 2000, 6(11):4217-4225.
  • 5Ohtsuka K, Ohnishi H, Furuyashiki G, et al. Clinicopathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma [ J ] . J Thorac Oncol, 2006, 1(8):787-795.
  • 6Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression [ J ] . Oncologist, 2002, 7 (Suppl 4):31-39.
  • 7Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification [ J ] . Cancer, 1994, 74(3):795-804.
  • 8Yaden Y, Sliwkowski MX. Untangling the ErbB signaling network [ J ] , Nat Rev Mol Biol, 2001, 2 (2) :127-137.
  • 9Moscatello DK, Montgomery RB, Sundareshan P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor [ J ] . Oncogene, 1996, 13(1): 85 -96.
  • 10Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvⅢ in high malignancy grade astrocytomas and evaluation of prognostic significance [ J ]. J Neuropathol Exp Neurol, 2004,63(7) :700 -707.

引证文献5

二级引证文献14

中华肿瘤防治杂志
2007年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部